Cost of H7N9 outbreak tops $6.5B; Sanofi's Indian vaccine biz preps for WHO visit;

@FiercePharma: What we talk about when we talk about pharma. Commentary | Join our LinkedIn group | Follow @FiercePharma

> The United Nations reports the H7N9 bird flu outbreak has cost $6.5 billion so far. Item

> Sanofi-owned Shantha Biotech is readying its 5-in-1 vaccines for re-inspection by the WHO. News

> Low vaccination rates in Ukraine could allow polio to re-enter Europe. Feature

> A TEDGlobal presentation has talked up the potential of a needle-free vaccine patch. Article

> Immunomic Therapeutics has raised $3 million to develop a Japanese red cedar allergy vaccine. Piece

> A study has found no evidence the MMR vaccine worsens juvenile arthritis. Study

> Brazil is to produce a H1N1 vaccine. Item

> Iran has reportedly succeeded in producing a vaccine for foot and mouth disease. News

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.